JP7051132B2 - ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法 - Google Patents

ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法 Download PDF

Info

Publication number
JP7051132B2
JP7051132B2 JP2019514710A JP2019514710A JP7051132B2 JP 7051132 B2 JP7051132 B2 JP 7051132B2 JP 2019514710 A JP2019514710 A JP 2019514710A JP 2019514710 A JP2019514710 A JP 2019514710A JP 7051132 B2 JP7051132 B2 JP 7051132B2
Authority
JP
Japan
Prior art keywords
adenovirus
composition
vector
freeze
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019514710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531288A5 (enExample
JP2019531288A (ja
Inventor
ケムター，クリスティナ
ショルツ，マルティン
Original Assignee
ロイコケア・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロイコケア・アクチェンゲゼルシャフト filed Critical ロイコケア・アクチェンゲゼルシャフト
Publication of JP2019531288A publication Critical patent/JP2019531288A/ja
Publication of JP2019531288A5 publication Critical patent/JP2019531288A5/ja
Application granted granted Critical
Publication of JP7051132B2 publication Critical patent/JP7051132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019514710A 2016-09-16 2017-09-15 ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法 Active JP7051132B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16189276 2016-09-16
EP16189276.5 2016-09-16
PCT/EP2017/073370 WO2018050872A1 (en) 2016-09-16 2017-09-15 A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy

Publications (3)

Publication Number Publication Date
JP2019531288A JP2019531288A (ja) 2019-10-31
JP2019531288A5 JP2019531288A5 (enExample) 2020-07-30
JP7051132B2 true JP7051132B2 (ja) 2022-04-11

Family

ID=57083083

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514710A Active JP7051132B2 (ja) 2016-09-16 2017-09-15 ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法

Country Status (5)

Country Link
US (2) US11166915B2 (enExample)
EP (1) EP3512939A1 (enExample)
JP (1) JP7051132B2 (enExample)
CN (1) CN109952372A (enExample)
WO (1) WO2018050872A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018050872A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
WO2018050873A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
KR102646145B1 (ko) 2018-05-31 2024-03-11 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
WO2020023612A1 (en) * 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
KR102058961B1 (ko) 2018-07-28 2019-12-24 주식회사 엑소코바이오 엑소좀의 동결건조 방법
KR102163806B1 (ko) * 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
KR102288367B1 (ko) 2018-11-15 2021-08-11 주식회사 바이오앱 식물체에서 바이러스-유사 입자를 발현하는 재조합 벡터 및 이를 이용한 써코바이러스-유사 입자를 포함하는 백신 조성물의 제조방법
CN112138153B (zh) * 2019-06-28 2022-08-23 怡道生物科技(苏州)有限公司 一种重组带状疱疹疫苗组合物及其用途
US20220325250A1 (en) 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
CA3180446A1 (en) * 2020-05-28 2021-12-02 Ahmed BESHEER Formulations for viral vectors
EP4598572A1 (en) * 2022-10-04 2025-08-13 Emergent Product Development Gaithersburg Inc. Novel vsv virus formulations
CN117065720B (zh) * 2023-07-21 2025-08-22 湖南新九方科技有限公司 一种热解生物炭吸附材料及其制备方法和应用
WO2025125222A1 (en) * 2023-12-11 2025-06-19 Leukocare Ag Compositions comprising viruses, viral vectors or virus-like particles
CN119548638B (zh) * 2025-01-21 2025-10-24 金宇保灵生物药品有限公司 一种活疫苗耐热保护剂及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009516519A (ja) 2005-11-21 2009-04-23 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
JP2014523243A (ja) 2011-06-28 2014-09-11 ロイコケア・アクチェンゲゼルシャフト ウイルスまたは細菌の新規な安定化方法
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
WO2015059284A1 (en) 2013-10-25 2015-04-30 Leukocare Ag A novel method for the production of stabile vaccines

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718889A1 (de) 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
DE19508192A1 (de) 1995-03-09 1996-09-12 Behringwerke Ag Stabile Transglutaminasepräparate und Verfahren zu ihrer Herstellung
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DK1610820T4 (da) 2003-04-04 2013-11-04 Genentech Inc Høj-koncentration antistof- og proteinformuleringer
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
EP4170024A1 (en) 2004-06-01 2023-04-26 Genzyme Corporation Compositions and methods to prevent aav vector aggregation
PL1778723T3 (pl) 2004-08-17 2013-03-29 Regeneron Pharma Preparaty antagonisty IL-1
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
EP1834651A1 (en) * 2006-03-15 2007-09-19 Universiteit Gent Compositions and methods for veterinary vaccination
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
GB0715723D0 (en) 2007-08-11 2007-09-19 Ark Therapeutics Ltd Formulation
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US7998488B2 (en) 2008-11-14 2011-08-16 Baxter International Inc. Vaccine formulations and uses thereof
EP2236520A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US9610343B2 (en) * 2009-05-20 2017-04-04 Aeras Global Tb Vaccine Foundation Stable, spray dryed, immunogenic, viral compositions
US8557253B2 (en) 2009-10-07 2013-10-15 Sanofi Pasteur Sa Stabilizing excipient for inactivated whole virus vaccine
CN102188701A (zh) * 2010-03-12 2011-09-21 上海泽润生物科技有限公司 一种磷酸铝佐剂及其制备方法
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
JP5798356B2 (ja) 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
US9453067B2 (en) 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
WO2012177970A1 (en) * 2011-06-24 2012-12-27 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
EP3511336B1 (en) 2011-06-28 2023-06-21 Leukocare Ag Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide
ES2971444T3 (es) 2011-10-11 2024-06-05 F Hoffmann Lar Roche Ag Ensamblaje mejorado de anticuerpos biespecíficos
CA2951856A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
HK1207312A1 (en) 2012-06-25 2016-01-29 新兴产品开发盖瑟斯堡有限公司 Temperature stable vaccine formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CA2926384A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
KR20160030963A (ko) 2013-07-11 2016-03-21 시노팜 타이완 리미티드 황산화 올리고당을 검출하기 위한 분석 방법
CN105039358B (zh) * 2013-12-03 2020-02-28 北京康乐卫士生物技术股份有限公司 58型重组人乳头瘤病毒病毒样颗粒及其制备方法
US20180028593A1 (en) 2014-03-21 2018-02-01 Boreal Invest Terminal nanofiltration of solubilized protein compositions for removal of immunogenic aggregates
AU2015357225B2 (en) * 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
WO2018050873A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
JP7170329B2 (ja) 2016-09-16 2022-11-14 ロイコケア・アクチェンゲゼルシャフト 処理中の生物医薬製品の安定化のための新規な方法
WO2018050872A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy
WO2018050874A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method of producing a liquid biopharmaceutical drug product

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009516519A (ja) 2005-11-21 2009-04-23 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
JP2014523243A (ja) 2011-06-28 2014-09-11 ロイコケア・アクチェンゲゼルシャフト ウイルスまたは細菌の新規な安定化方法
WO2015040234A1 (en) 2013-09-23 2015-03-26 Crucell Holland B.V. Adenovirus formulations
WO2015059284A1 (en) 2013-10-25 2015-04-30 Leukocare Ag A novel method for the production of stabile vaccines

Also Published As

Publication number Publication date
US20220202717A1 (en) 2022-06-30
WO2018050872A1 (en) 2018-03-22
CN109952372A (zh) 2019-06-28
US11166915B2 (en) 2021-11-09
EP3512939A1 (en) 2019-07-24
US20190269618A1 (en) 2019-09-05
US12350375B2 (en) 2025-07-08
JP2019531288A (ja) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7051132B2 (ja) ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
JP7358068B2 (ja) 熱安定性ワクチン製剤及びマイクロニードル
Knuschke et al. Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection
US8313897B2 (en) Method for preserving viral particles
JP6417217B2 (ja) ウイルスまたは細菌の新規な安定化方法
DK2552465T3 (en) Stabilization of virus particles
CA2873775C (en) Herpesvirus compositions and related methods
US20230277654A1 (en) Stable formulations of cytomegalovirus
TWI883381B (zh) ｍＲＮＡ分子、ＤＮＡ分子、重組質體、脂質奈米顆粒、藥物組合物、新型冠狀病毒ｍＲＮＡ疫苗及其製備方法與用途
Scherließ et al. Induction of protective immunity against H1N1 influenza A (H1N1) pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates
JP7406377B2 (ja) 安定なウイルス含有組成物
Zhang et al. Coxsackievirus B5 virus-like particle vaccine exhibits greater immunogenicity and immunoprotection than its inactivated counterpart in mice
Renteria et al. Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices
US20220325250A1 (en) Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
Zhang et al. Exosome-based delivery of VP1 protein conferred enhanced resistance of mice to CVB3-induced viral myocarditis
Buonaguro et al. Virus-like particle vaccines and adjuvants: the HPV paradigm
WO2024211446A1 (en) Compositions and methods for making and using stabilized enveloped viruses by spray-drying and lyophilization
WO2025125222A1 (en) Compositions comprising viruses, viral vectors or virus-like particles
Boquet Optimization of poly (DL-lactide-co-glycolide) microsphere production for oral delivery to promote adenovirus stability and intestinal gene transfer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220323

R150 Certificate of patent or registration of utility model

Ref document number: 7051132

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250